Tartirelin is mainly used to improve motor dysfunction symptoms in patients with spinal cord cerebellar degeneration. Its therapeutic effect needs to be evaluated individually, and the principle of gradual withdrawal should be followed when stopping the medication to avoid withdrawal reactions. The following provides a detailed explanation from two aspects: evaluation of treatment efficacy and precautions for discontinuing medication.

1. Therapeutic effect

(1) Clinical efficacy

Regarding spinocerebellar degeneration, about 60% of patients show improvement in motor coordination after medication, manifested as increased gait stability and fine motor control. The therapeutic effect usually appears 2-4 weeks after medication.

(2) Differences in therapeutic efficacy

Patients with high sensitivity to TRH receptors have a more significant response, and about 30% of patients may not show significant improvement, requiring the combination of other rehabilitation treatments.

(3) Maintain time

Continuous medication can maintain efficacy, but some patients may experience a decrease in efficacy, requiring regular evaluation and necessary adjustment of dosage.

2. Precautions for discontinuation of medication

(1) Indications for discontinuation of medication

When severe allergic reactions, persistent tachycardia, or loss of efficacy occur, discontinuation of medication should be considered and should be carried out under the guidance of a doctor.

(2) Discontinuation method

The stepwise reduction method should be adopted, reducing the original dose by 25% every 3-5 days, with a total reduction period of no less than 2 weeks, to avoid sudden cessation of medication causing rebound movement disorders.

(3) Medication withdrawal monitoring

During the cessation of medication, it is necessary to closely observe changes in motor function. If existing symptoms worsen or new tremors occur, the dosage should be temporarily reduced and medical evaluation should be sought.

(4) Special populations

Elderly patients and those with liver and kidney dysfunction should extend their medication reduction period to 3-4 weeks, while pediatric patients should discontinue medication under the supervision of a specialist.

(5) Subsequent management

After complete discontinuation of medication, it is recommended to continue follow-up for 3 months, conduct regular neurological function assessments, and consider alternative treatment options if necessary.